HER3 protein levels at the cancer cell plasma membrane are directly correlated with reduced survival in colorectal cancer (CRC) patients. In CRC cells, HER3 blockade restricted cellular growth (G2/M arrest), survival, migration, invasion and potentiated the chemotherapeutic effect of 5-FU, supporting strategies targeting HER3 in subsets 3of CRC patients.
In this issue of Clinical Cancer Research, Beji and colleagues (1) report that the HER3 pseudo-kinase is overexpressed in a series of clinical primary colorectal tumors and derived CRC cell lines. Remarkably, CRC patients with high HER3 expression had shorter survival times than cases with lower expression. Moderate and high HER3 expression was identified as an independent prognostic marker for low survival associated with a relative risk of 3.29.
The HER1 prototype of the epidermal growth factor EGFR/HER family comprising HER2 (ErbB-2), HER3 and HER4 has been identified as a critical player in the progression of epithelial neoplasms, including CRC. HER agonists initiate receptor homo-or heterodimerization and connections with a vast array of intracellular signaling pathways through paracrine and autocrine loops ( 
conversely promotes up-regulation of the CDK inhibitor p27(Kip). Thus, global accumulation of p27 observed in HER3 silenced cells may reflect the downregulation of PI3K associated with p27 stability (8) . Moreover, the PI3K/AKT/mTOR axis has been shown to regulate the accumulation, translocation and activity of p27 in nuclear and cytoplasmic compartments according to loss and gain of p27 functions (8, 9) . Consistently, p27 is described as a double-faceted molecular player acting as tumor suppressor and negative regulator of cancer cell growth versus its invasion/metastasis promoter activity, pending its nuclear/cytoplasmic localization (8- 
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